Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have revolutionized the treatment of EGFR-mutant non-small cell lung cancer; however, secondary resistance limits their efficacy, emphasizing the need for newer approaches. A study now shows preclinical development of allosteric EGFR inhibitors that overcome acquired therapy resistance.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Siegel, R. L. et al. CA Cancer J. Clin. 72, 7–33 (2022).
Midha, A., Dearden, S. & McCormack, R. Am. J. Cancer Res. 5, 2892–2911 (2015).
Lynch, T. J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).
Passaro, A. et al. Nat. Cancer 2, 377–391 (2021).
To, C. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00351-8 (2022).
Ramalingam, S. S. et al. N. Engl. J. Med. 382, 41–50 (2020).
Mok, T. S. et al. N. Engl. J. Med. 376, 629–640 (2017).
Igawa, S. et al. Cancer Manag. Res. 11, 4883–4892 (2019).
Jia, Y. et al. Nature 534, 129–132 (2016).
To, C. et al. Cancer Discov. 9, 926–943 (2019).
Leahy, D. J. Cell 142, 513–515 (2010).
Rodrik-Outmezguine, V. S. et al. Nature 534, 272–276 (2016).
Mullard, A. Nat. Rev. Drug Discov. 20, 806 (2021).
S.M. has served as a consultant for Boehringer Ingelheim. M.M. declares no competing interests.
About this article
Cite this article
Marasco, M., Misale, S. Resistance is futile with fourth-generation EGFR inhibitors. Nat Cancer 3, 381–383 (2022). https://doi.org/10.1038/s43018-022-00365-2